Development trends for new cancer therapeutics and vaccines

Area of Science:

• Oncology
• Pharmaceutical Development
• Clinical Trials

Background:

• Global development of cancer treatments has significantly expanded in recent years.
• Assessing trends in cancer therapeutic development is crucial for understanding the drug pipeline.
• The period 1990-2006 saw a rise in candidates entering clinical studies for cancer.

Purpose of the Study:

• To analyze trends in the commercial development of cancer treatments.
• To evaluate the success rates and timelines of cancer drug candidates in clinical studies and US approval.
• To identify areas for improvement in the cancer drug development process.

Main Methods:

• Analysis of data for 1111 cancer therapeutic candidates entering clinical study between 1990 and 2006.
• Examination of trends in the number of therapeutic candidates per year.
• Assessment of US approval success rates and average time for clinical and approval phases.

Main Results:

• The number of cancer therapeutic candidates entering clinical study more than doubled annually.
• The US approval success rate for cancer treatments during the study period was low, at 8%.
• Cancer therapeutics took an average of seven years to complete clinical and US approval phases; cancer vaccines had no US approvals.

Conclusions:

• Despite increased development, the cancer treatment pipeline faces low approval success rates.
• Significant improvements are needed to enhance the efficiency of developing innovative cancer therapies.
• The lack of US approvals for cancer vaccines indicates a specific challenge within this therapeutic class.